Study finds weight-loss drugs may lower risk of 42 health conditions in diabetes patients

A new study shows that diabetes patients using GLP-1 receptor agonists, found in weight-loss drugs like Saxenda and Wegovy, have a lower risk of 42 health conditions, including dementia and infections. This research suggests potential benefits beyond diabetes treatment. The study analyzed health records of nearly 1.5 million individuals, revealing a 19% reduced risk for bulimia and 12% for Alzheimer's disease among those taking GLP-1RAs. However, it also noted increased risks for 19 conditions, such as abdominal pain and kidney stones. Researchers emphasize that while benefits may extend to non-diabetic users, weight loss could influence outcomes. Further studies are needed to explore these associations and their implications for new treatments.